862120-75-0

Basic information

• Product Name: 2-Bromomethyl-6-chloro-4-(trifluoromethyl)pyridine
• Synonyms: 2-Bromomethyl-6-chloro-4-(trifluoromethyl)pyridine
• CAS NO: 862120-75-0
• Molecular Formula: C₇H₄BrClF₃N
• Molecular Weight: 274.47
• Mol File: 862120-75-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 236.7±35.0 °C(Predicted)
• Appearance: /
• Density: 1.741±0.06 g/cm3(Predicted)
• PKA: -2.72±0.10(Predicted)
• CAS DataBase Reference: 2-Bromomethyl-6-chloro-4-(trifluoromethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromomethyl-6-chloro-4-(trifluoromethyl)pyridine(862120-75-0)
• EPA Substance Registry System: 2-Bromomethyl-6-chloro-4-(trifluoromethyl)pyridine(862120-75-0)

Safety Data

• Hazardous Substances Data: 862120-75-0(Hazardous Substances Data)

Upstream product

• 22123-14-4 2-chloro-6-methyl-4-(trifluoromethyl)pyridine 

Downstream Products

• 1004794-07-3 tert-butyl 4-(((6-chloro-4-(trifluoromethyl)pyridine-2-yl)methoxy)methyl)-4-phenylpiperidine-1-carboxylate 
• 1004794-09-5 tert-butyl 4-(((6-chloro-4-(trifluoromethyl)pyridine-2-yl)methoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 862120-77-2 C₇H₆ClF₃N₂ 
• 2144425-14-7 6,6-dimethyl-8-[7-(trifluoromethyl)imidazo[1,5-a]pyridin-5-yl]-1,3,8-triazaspiro[4.5]decane-2,4-dione 
• 1004794-23-3 C₁₉H₁₉ClF₄N₂O 
• 1416949-06-8 C₂₅H₂₉F₄N₃O 

Relevant articles and documents

COMPOUNDS

Compounds of formula (IA) and formula (IB), which are useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase, are provided. Also provided are pharmaceutical compositions, kits comprising said compounds, and methods and uses pert

NOVEL SUBSTITUTED IMIDAZOPYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN-2,3-DIOXYGENASE

Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.

SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.